Management indicated plans to provide both regulatory and clinical trial updates on blarcamesine for indications beyond Alzheimer’s, including Parkinson’s disease, Rett syndrome, and Fragile X.

Most traders aren't short on information. They're short on consistency. One day they stick to their rules. The next day they tweak everything because a few candles looked 'different.' That pattern ...